Zenodo
Is SGLT-2i recommended for patients with CKD G3aA1 to improve hard outcomes?
By Tripdatabase.
Abstract
SGLT-2 inhibitors are recommended for patients with CKD G3aA1 for improving hard outcomes such as reducing progression to end-stage kidney disease and lowering mortality.
Keywords
- Chronic Kidney Disease and Diabetes
- SGLT2 inhibitors
- end-stage kidney disease progression
- mortality
- drug recommendation
- Open access
Source
Published in Zenodo (CERN European Organization for Nuclear Research). The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
At a glance
- Journal
- Zenodo